View Older Stories
-
Revvity schedules earnings call and raises guidance above range
-
Raymond James Reiterates Outperform Rating on Revvity Inc (RVTY)
-
Revvity launches Signals Xynthetica AI platform for molecular design
-
BofA Securities Downgrades Revvity Inc (RVTY) to Neutral
-
Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy
-
Goldman Sachs Starts Revvity Inc (RVTY) at Neutral
-
Revvity, Inc. (RVTY) Tops Q3 EPS by 4c, provides guidance
-
Guggenheim Starts Revvity Inc (RVTY) at Neutral
-
Revvity partners with Sanofi to develop type 1 diabetes screening test
-
Revvity launches AI software for preclinical imaging analysis
-
KeyBanc: 'Revvity Inc (RVTY) an Attractive Name for Value Investors'
-
Revvity Inc (RVTY) PT Lowered to $110 at Stifel
-
Revvity Inc (RVTY) PT Lowered to $115 at Raymond James
-
Revvity Inc (RVTY) PT Lowered to $115 at Bernstein on Lower Estimates
-
Revvity (RVTY) 968 contracts trade as share price down 8.8%
-
Revvity Inc (RVTY) PT Lowered to $100 at Jefferies
-
Revvity, Inc. (RVTY) Tops Q2 EPS by 4c, provides guidance
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
AstroNova (ALOT) Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Buy this stock as investor China concerns 'are overblown': UBS
-
UBS Upgrades Revvity Inc (RVTY) to Buy
-
Stifel Reiterates Hold Rating on Revvity Inc (RVTY)
-
Revvity (RVTY) call put ratio 2.7 calls to 1 put
-
Revvity, Inc. (RVTY) Tops Q1 EPS by 6c, provides guidance
-
KeyBanc on Revvity Inc (RVTY): 'Why We Believe FY25 Is Achievable'
-
Revvity (RVTY) Secures FDA Approval for Improved Automated Latent Tuberculosis Test
-
Evercore Adds 7 Names to Tactical Outperform List
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Revvity Inc (RVTY) PT Raised to $145 at KeyBanc, Citing 'Organic Growth Guidance'
-
Stifel Reiterates Hold Rating on Revvity Inc (RVTY)
-
Stifel Reiterates Hold Rating on Revvity Inc (RVTY)
-
Revvity Inc (RVTY) PT Raised to $140 at Bernstein ON Growth Potential
-
Revvity Inc (RVTY) PT Raised to $130 at Jefferies
-
Revvity, Inc. (RVTY) Tops Q4 EPS by 5c, initiates full year 2025 guidance
-
Revvity (RVTY) Declares $0.07 Quarterly Dividend; 0.2% Yield
-
Bernstein SocGen Group Downgrades Revvity Inc (RVTY) to Market Perform
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Revvity Inc (RVTY) PT Raised to $144 at TD Cowen
-
Revvity Inc (RVTY) PT Raised to $138 at Baird
-
KeyBanc Reiterates Overweight Rating on Revvity Inc (RVTY)
-
Revvity Inc (RVTY) PT Raised to $134 at Evercore ISI
-
Revvity, Inc. (RVTY) Tops Q3 EPS by 15c; raises guidance
-
Revvity (RVTY) Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
-
Barclays Upgrades Revvity Inc (RVTY) to Overweight
-
3 ways to gain stock market exposure to the fertility theme
-
Revvity Inc (RVTY) PT Raised to $141 at TD Cowen
-
Revvity Inc (RVTY) PT Raised to $136 at Baird
-
Revvity Inc (RVTY) PT Raised to $127 at BofA Securities
-
Revvity Inc (RVTY) PT Raised to $125 at Jefferies

